Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | CRHBP | P24387 | 3/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843804 | 0.85 | MEN1 (0.48) | SMN1; SMN2MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL7422107 | 0.83 | ALDH1A1 (0.52) | SMN1; SMN2MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL4619084 | 0.73 | ALDH1A1 (0.47) | SMN1; SMN2MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL1608610 | 0.73 | ALOX15 (0.58) | SMN1; SMN2KMT2ANPSR1RAB9AALDH1A1 | |
| SCHEMBL6582296 | 0.70 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL1967194 | 0.70 | ALDH1A1 (0.49) | SMN1; SMN2MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL8966773 | 0.70 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL1843975 | 0.70 | ALDH1A1 (0.59) | SMN1; SMN2KMT2ANPSR1RAB9AALDH1A1 | |
| SCHEMBL1974278 | 0.70 | L3MBTL1 (0.50) | SMN1; SMN2MEN1KMT2ANPSR1RAB9A | |
| SCHEMBL17042260 | 0.69 | NPSR1 (0.55) | SMN1; SMN2MEN1KMT2ANPSR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320897-B1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
| EP-2320897-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | Treventis Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010025375-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | SMN1; SMN2 84/4885MEN1 2995/4885KMT2A 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.